Iron deficiency anemia (IDA) remains a widespread global health challenge, impacting millions and leading to fatigue, reduced physical capacity, and diminished quality of life. While oral iron supplements are often the first line of treatment, their efficacy can be limited by gastrointestinal side effects, poor absorption, or patient intolerance. This necessitates the development of more effective and well-tolerated therapeutic alternatives. Among these, Ferric Carboxymaltose (FCM) stands out as a highly effective intravenous iron replacement product, offering a superior approach to rapidly replenish iron stores.

Ferric Carboxymaltose, identified by its CAS number 9007-72-1, is a sophisticated iron carbohydrate complex. Chemically, it consists of polynuclear iron (III) hydroxide cores stabilized by a carbohydrate shell of carboxymaltose, a high-molecular-weight polysaccharide. This intricate structure is key to its therapeutic advantages. Unlike simpler iron salts, FCM’s stable complex allows for a controlled release of iron into the bloodstream, minimizing the burst of free iron that can lead to oxidative stress and adverse reactions. It is typically supplied as a fine powder, ranging in color from white to red-brown, and exhibits excellent solubility in water, making it ideal for intravenous administration.

The primary application of Ferric Carboxymaltose is in the treatment of iron deficiency anemia in adult and pediatric patients (aged 1 year and older) who either cannot tolerate oral iron or have not achieved a satisfactory response with oral therapy. Its utility extends significantly to patients with non-dialysis dependent chronic kidney disease, where oral iron absorption is often compromised. Furthermore, FCM has shown remarkable benefits in patients with iron deficiency and mild to moderate heart failure, improving their exercise capacity and overall well-being. Other critical applications include perioperative management to correct preoperative anemia, treatment of iron deficiency in pregnant women, and management of gastrointestinal disorders where iron absorption is impaired.

The benefits of intravenous Ferric Carboxymaltose are multifaceted. It provides a rapid and efficient method for iron replenishment, often requiring fewer administrations compared to other intravenous iron therapies. Its unique chemical properties contribute to a higher safety margin, with a lower incidence of hypersensitivity reactions, including anaphylaxis, when compared to older intravenous iron preparations. The high bioavailability ensures that the administered iron is effectively utilized by the body to synthesize hemoglobin and replenish depleted iron stores, leading to a swift improvement in anemia symptoms and patient outcomes.

At NINGBO INNO PHARMCHEM CO.,LTD., our dedication to producing high-quality active pharmaceutical ingredients ensures that our Ferric Carboxymaltose meets stringent pharmaceutical standards. Manufactured under rigorous quality control measures, our product adheres to international pharmacopoeia standards such as USP, ensuring consistent potency, purity, and safety. We pride ourselves on offering a product that supports global healthcare needs with reliability and excellence.

For those seeking to buy Ferric Carboxymaltose, comparing Ferric Carboxymaltose price options, or needing a dependable Ferric Carboxymaltose supplier, NINGBO INNO PHARMCHEM CO.,LTD. stands as a premier Ferric Carboxymaltose manufacturer. We offer flexible minimum order quantities and efficient lead times to meet the diverse demands of the pharmaceutical industry worldwide. Our comprehensive quality assurance includes certifications like MSDS, HALAL, COA, ISO9001, and ISO22000, underscoring our commitment to providing a product that healthcare professionals can trust. We are ready to support your production needs with a superior pharmaceutical grade product.